Members Archive - MassBio

Skyhawk Therapeutics

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

Skyhawk Therapeutics is committed to discovering, developing and commercializing therapies that use its novel STAR* (Small molecule Therapies for Alternative splicing in RNA) platform to build small molecule drugs that bring breakthrough treatments to patients.

For more information about the company, please visit our website www.skyhawktx.com, Twitter or LinkedIn pages.

The post Skyhawk Therapeutics appeared first on MassBio.

Sophion Bioscience Inc.

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

[From Sophia + Ion: Greek σοφία, “wisdom” the ability to think and act using knowledge, experience, understanding and insight, the capacity of judging rightly]

Sophion was founded almost twenty years ago by a group of passionate electrophysiologists, all having the shared purpose of making patch clamping objective and independent of user skills to provide faster, more accurate and objective patch clamping results. “To take the voodoo out of patch clamping”.

Over the past twenty years we have developed from a startup into a global organization, but the passion and drive to provide high performance patch clamp solutions persists.

With our complete technical, biological and application support we help our partners to achieve their targets, and through continued development of our QPatch and Qube platforms we ensure that we offer uncompromised data quality in a user-friendly environment from assay setup to data analysis.

The post Sophion Bioscience Inc. appeared first on MassBio.

Stealth BioTherapeutics

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

Stealth Peptides was founded in 2006 with technologies licensed from several academic institutions. Stealth Peptides has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500-700 Daltons each) that target mitochondria. Published data for these compounds suggest significant in vitro and in vivo efficacy for cardiovascular, renal, neurologic and metabolic diseases.The intellectual property portfolio around these compounds is incredibly robust with compositions including Bendavia protectable by patent until 2031.

The post Stealth BioTherapeutics appeared first on MassBio.

Tectonic Therapeutic

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

Tectonic is transforming the discovery of novel GPCR-targeted therapies

GPCRs whose natural ligands are peptides or proteins represent large untapped opportunities, best addressed with a biologic approach. Our science
unlocks the therapeutic utility of the most difficult receptors in the class, to date considered undruggable with small molecule.

The post Tectonic Therapeutic appeared first on MassBio.

Visterra, Inc.

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

Visterra is focused on the discovery and development of innovative products that will transform the prevention and treatment of infectious diseases. Visterra’s groundbreaking technology platform, built around its unique structural understanding of how a virus docks to receptor cell surface glycans (complex sugars), enables the company to rationally design more effective therapeutics and vaccines. The company has established proof of concept with its lead therapeutic product candidate for influenza.

The post Visterra, Inc. appeared first on MassBio.

Vizgen, Inc

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

Vizgen is developing the next generation of spatially resolved genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease. The company’s MERSCOPE^TMplatform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.

The post Vizgen, Inc appeared first on MassBio.

Vigil Neuroscience, Inc.

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

Founded in 2020, Vigil Neuroscience is a rapidly growing startup biotechnology company taking innovative approaches to treating both rare and common diseases of the central nervous system. We focus on the research and development of both small and large molecule drugs that can positively modulate neuroinflammation through modifying the biology of the principal innate immune system cell of the CNS, the microglia. We are patient-focused and strive to discover, research, develop and clinically test innovative medicines to improve the lives of those suffering from debilitating and lethal neurological conditions.

The post Vigil Neuroscience, Inc. appeared first on MassBio.

Transition Bio

wpengine — Tue, 02 Jan 2024 17:33:10 +0000

The post Transition Bio appeared first on MassBio.

PROMETRIKA, LLC

wpengine — Tue, 02 Jan 2024 17:33:09 +0000

PROMETRIKA, LLC is a clinical research organization (CRO) supporting the biopharmaceutical and medical device industries since 2003. Based in Cambridge, Massachusetts, a biopharmaceutical hub, PROMETRIKA has provided more than a decade of experienced, professional support to local, national, and international clients. Our proximity to New England’s thriving biotechnology research environment has enabled us to establish strong, collaborative relationships with companies developing some of the most innovative and promising new therapies available. We offer full services in clinical operations, data management, biostatistics and programming, medical writing, and regulatory submissions. For those clients with a full range of in-house competencies, we can provide stand-alone, focused services. For those clients with limited infrastructure, we can provide integrated, full-service solutions that incorporate the full spectrum of our offerings. Our size allows us to be competitive and efficient in meeting time-sensitive budgetary restrictions without sacrificing the quality of deliverables. We always strive to maintain high-value services while remaining flexible in response to your needs. We are internally structured to quickly scale up or scale down as needed. PROMETRIKA’s highest priorities are the quality of our work and adherence to regulatory requirements. All deliverables are subject to rigorous quality control procedures by our highly trained staff, resulting in accurate deliverables without compromising efficiency. Our management team has a long history of successful collaboration and is committed to our core values of quality, integrity, and innovation. To maintain our rigorous quality control standards, we do not subcontract services except for monitoring outside North America, which we entrust to fully qualified partners. We firmly believe in transparency across all clinical and business processes.

The post PROMETRIKA, LLC appeared first on MassBio.

Pyxis Oncology, Inc.

wpengine — Tue, 02 Jan 2024 17:33:09 +0000

Pyxis Oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment.

The post Pyxis Oncology, Inc. appeared first on MassBio.